Skip to main content
. 2020 Nov 13;10:541262. doi: 10.3389/fonc.2020.541262

Figure 2.

Figure 2

Down regulation of MTA1 sensitized gemcitabine-induced tumor growth regression in MCF-7 cell lines. (1) WB and statistics for small interfere RNA (siRNA) induced MTA1 knockdown in breast cancer cell lines: MCF-6, MBA-MD-231 and 4T1 (A1-2–C1-2). (2) viability of cells, tested by MTT after 48h-treatment of siRNA and 72h culturing in 96-wells plates (A3–C3). (3) cells are treated with siRNA for 48h followed by 48h-treatment of DMSO, 5μM gemcitabine or 10μM of gemcitabine (A4–C4). (4) Stable knockdown of MTA1 in MCF-7 and MBA-MD-231 cells, verified by WB (D, E, G2). (5) Cloning formation of WT_ MCF-7/MBA-MD-231(i), NC_ MCF-7/MBA-MD-231(ii) and shMTA1_MCF-7/MBA-MD-231(iii) cells (F, G1). (6) NC_ MCF-7 and shMTA1_MCF-7 are treated with gemcitabine or DMSO for 48h, and then are cultured in fresh complete medium for 5 days, in which cells are tested for viability through MTT every day, and cell growth was inhibited as compared with NC (H1, H2). (7) NC_MBA-MD-231 and siMTA_MBA-MD-231 cells are treated with gemcitabine or DMSO for 48h, and then are cultured in fresh complete medium for 5 days, which cells are tested for viability through MTT every day, and cell growth was inhibited as compared with NC (I1, I2).